Mild Cognitive Impairment Market Anticipated to Expand Rapidly During 2024-2034, Says DelveInsight
DelveInsight's 'Mild Cognitive Impairment Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Mild Cognitive Impairment, historical and forecasted epidemiology as well as the Mild Cognitive Impairment market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
Some of the key facts of the Mild Cognitive Impairment Market Report:
The Mild Cognitive Impairment market size was valued ~USD 2,836 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).
In April 2025, At the AD/PD 2025 International Conference on Alzheimer's and Parkinson's Diseases, Alzheon shared findings from its Phase III APOLLOE4 (NCT04770220) trial during a company-sponsored symposium. The study evaluated ALZ-801 (valiltramiprosate), an oral small molecule that blocks the formation of neurotoxic amyloid beta (Aβ) oligomers, in patients with early-stage Alzheimer's disease—specifically those with mild cognitive impairment (MCI) or mild Alzheimer's—who are homozygous carriers of the APOE4 gene.
In December 2024, Blarcamesine (ANAVEX2-73) has been accepted for review by the EMA for the treatment of Alzheimer's disease. This submission was supported by positive findings from the ANAVEX2-73-AD-004 clinical trial, which involved patients in the early stages of Alzheimer's.
As of December 2024, TauRx is actively engaging with the Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE) concerning its UK Marketing Authorisation Application (MAA) for hydromethylthionine mesylate (HMTM), a 4 mg oral tablet aimed at treating mild cognitive impairment due to Alzheimer's (MCI-AD) and mild to moderate Alzheimer's disease.
In July 2024, The US FDA has granted approval to KISUNLA (donanemab-azbt, 350 mg/20 mL), an Alzheimer's treatment developed by Eli Lilly. The therapy is intended for adults with early symptomatic Alzheimer's disease, including those with mild cognitive impairment (MCI) and mild dementia confirmed to have amyloid pathology.
In October 2024, AgeneBio reported that its Phase 2B trial of AGB101 showed a 40% reduction in clinical decline and notable slowing of entorhinal cortex atrophy in patients with mild cognitive impairment (MCI) due to Alzheimer's disease who are non-carriers of the ApoE-4 allele, compared to placebo. The ongoing findings from the HOPE4MCI trial strongly support continued evaluation of AGB101 in this specific patient group. The company is currently conducting an extension of the study in the US (NCT05986721).
In 2023, the United States held the largest market share for Mild Cognitive Impairment among the 7MM, with an estimated value of around USD 1,467 million, and this figure is projected to grow by 2034.
The existing Mild Cognitive Impairment market comprises approved treatments like LEQEMBI (lecanemab) and off-label options such as cholinesterase inhibitors, memantine, and others, collectively reaching a market size of USD 222 million across the 7MM in 2023.
In 2023, Japan's Mild Cognitive Impairment market was valued at approximately USD 670 million, representing around 24% of the total 7MM market, with projections indicating further growth by 2034.
According to DelveInsight's analysis, the estimated number of diagnosed prevalent cases of Parkinson's disease in the US reached approximately 1.21 million in 2023.
In 2023, Germany reported the highest number of diagnosed prevalent Alzheimer's disease cases among European countries, with around 1.49 million cases. France followed with approximately 1.17 million cases, while the UK had the lowest prevalence, with about 620 thousand diagnosed individuals.
In Japan, around 2.73 million diagnosed cases of Mild Cognitive Impairment were recorded, with approximately 103,000 linked to Parkinson's disease and about 2.63 million associated with Alzheimer's. Forecasts indicate that by 2034, cases related to Alzheimer's will rise further, continuing to outnumber those related to Parkinson's, emphasizing the growing burden of Alzheimer's on the aging population.
According to DelveInsight's analysis, the United States had the highest number of diagnosed prevalent cases of Mild Cognitive Impairment among the 7MM, with approximately 4.22 million cases reported in 2023. However, forecasts suggest that the United Kingdom is expected to surpass others and lead in diagnosed cases by 2034.
Key Mild Cognitive Impairment Companies: FUJIFILM Toyama Chemical Co. Ltd., Aptinyx, AgeneBio, Eisai Inc., RespireRx, Allon Therapeutics, CuraSen Therapeutics, Inc., Avraham Pharma, AstraZeneca, Sage Therapeutics, Pfizer, Materia Medica Holding, Eli Lilly and Company, GE Healthcare, Parexel, and others
Key Mild Cognitive Impairment Therapies: T-817MA, NYX-458, Aptinyx, T-817MA, Aricept (donepezil hydrochloride), CX516, AL-208, CST-2032, ladostigil hemitartrate, AZD5213, SAGE-718, fesoterodine, MMH-MAP, Donanemab, Flutemetamol (18F) Injection, EVP-0962, and others
The Mild Cognitive Impairment market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Mild Cognitive Impairment pipeline products will significantly revolutionize the Mild Cognitive Impairment market dynamics.
Mild Cognitive Impairment Overview
Between the predicted cognitive loss associated with normal ageing and the more substantial decline associated with dementia is a period known as mild cognitive impairment (MCI). It is characterised by issues with thinking, judgement, language, and memory.
Mild Cognitive Impairment Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Mild Cognitive Impairment Epidemiology Segmentation:
The Mild Cognitive Impairment market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Mild Cognitive Impairment Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Mild Cognitive Impairment market or expected to get launched during the study period. The analysis covers Mild Cognitive Impairment market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Mild Cognitive Impairment Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Mild Cognitive Impairment Therapies and Key Companies
LEQEMBI (lecanemab): Biogen Inc./Eisai Co., Ltd.
KISUNLA (Donanemab): Eli Lilly and Company
Valiltramiprosate (ALZ-801): Alzheon Inc.
Mirodenafil (AR1001): AriBio Co., Ltd.
Hydromethylthionine Mesylate (HMTM)/TRx0237: TauRx Therapeutics
T-817MA: FUJIFILM Toyama Chemical Co. Ltd.
NYX-458: Aptinyx
Aptinyx: AgeneBio
T-817MA: FUJIFILM Toyama Chemical Co., Ltd.
Aricept (donepezil hydrochloride): Eisai Inc.
CX516: RespireRx
AL-208: Allon Therapeutics
CST-2032: CuraSen Therapeutics, Inc.
ladostigil hemitartrate: Avraham Pharma
AZD5213: AstraZeneca
SAGE-718: Sage Therapeutics
fesoterodine: Pfizer
MMH-MAP: Materia Medica Holding
Donanemab: Eli Lilly and Company
Flutemetamol (18F) Injection: GE Healthcare
EVP-0962: Parexel
Discover more about therapies set to grab major Mild Cognitive Impairment market share @ Mild Cognitive Impairment Treatment Market
Scope of the Mild Cognitive Impairment Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Mild Cognitive Impairment Companies: FUJIFILM Toyama Chemical Co. Ltd., Aptinyx, AgeneBio, Eisai Inc., RespireRx, Allon Therapeutics, CuraSen Therapeutics, Inc., Avraham Pharma, AstraZeneca, Sage Therapeutics, Pfizer, Materia Medica Holding, Eli Lilly and Company, GE Healthcare, Parexel, and others
Key Mild Cognitive Impairment Therapies: T-817MA, NYX-458, Aptinyx, T-817MA, Aricept (donepezil hydrochloride), CX516, AL-208, CST-2032, ladostigil hemitartrate, AZD5213, SAGE-718, fesoterodine, MMH-MAP, Donanemab, Flutemetamol (18F) Injection, EVP-0962, and others
Mild Cognitive Impairment Therapeutic Assessment: Mild Cognitive Impairment current marketed and Mild Cognitive Impairment emerging therapies
Mild Cognitive Impairment Market Dynamics: Mild Cognitive Impairment market drivers and Mild Cognitive Impairment market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Mild Cognitive Impairment Unmet Needs, KOL's views, Analyst's views, Mild Cognitive Impairment Market Access and Reimbursement
Table of Contents
1. Mild Cognitive Impairment Market Report Introduction
2. Executive Summary for Mild Cognitive Impairment
3. SWOT analysis of Mild Cognitive Impairment
4. Mild Cognitive Impairment Patient Share (%) Overview at a Glance
5. Mild Cognitive Impairment Market Overview at a Glance
6. Mild Cognitive Impairment Disease Background and Overview
7. Mild Cognitive Impairment Epidemiology and Patient Population
8. Country-Specific Patient Population of Mild Cognitive Impairment
9. Mild Cognitive Impairment Current Treatment and Medical Practices
10. Mild Cognitive Impairment Unmet Needs
11. Mild Cognitive Impairment Emerging Therapies
12. Mild Cognitive Impairment Market Outlook
13. Country-Wise Mild Cognitive Impairment Market Analysis (2020–2034)
14. Mild Cognitive Impairment Market Access and Reimbursement of Therapies
15. Mild Cognitive Impairment Market Drivers
16. Mild Cognitive Impairment Market Barriers
17. Mild Cognitive Impairment Appendix
18. Mild Cognitive Impairment Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
11 hours ago
- CTV News
Japan's oldest person is a 114-year-old retired doctor who carried an Olympic torch in 2021
Shigeko Kagawa holds a torch during a torch relay event for the Tokyo Olympics in Yamatokooriyama, Nara prefecture, western Japan, April 12, 2021. (Kyodo News via AP) TOKYO — Shigeko Kagawa, a 114-year-old retired physician from Nara Prefecture, has became Japan's oldest living person, following the death of 114-year-old Miyoko Hiroyasu, according to Japan's Ministry of Health, Labor and Welfare. Kagawa, a symbol of Japan's extraordinary longevity, graduated from medical school before World War II, served at a hospital in Osaka during the war, and later ran her family's clinic as an obstetrician and gynecologist. She retired at 86. At 109, Kagawa became one of the oldest torchbearers in Olympic history during the Tokyo 2021 torch relay. She is not doing anything out of the ordinary to stay healthy, a local television MBS News said last week, quoting her family. She keeps a regular routine, going to bed and waking up at set times and she eats small portions but always has three proper meals a day. Her predecessor as Japan's oldest person led a similarly active life. Born in 1911, Hiroyasu studied art in Tokyo, taught in Hiroshima Prefecture and raised three children. She died in a nursing home in Oita Prefecture, where she spent her days reading newspapers, sketching and playing card games. 'I am grateful to be healthy,' she said on her 113th birthday. Despite an overall population decline, Japan's elderly population continues to grow. As of September 1, 2024, a record 36 million people — 29% of the population — were aged 65 or older, the highest proportion of seniors in the world. Those aged 80 and above now make up 10% of the population, according to the Ministry of Internal Affairs and Communications. There are 95,119 centenarians across the country. The Associated Press
National Post
15 hours ago
- National Post
Nucleus Network Acquires Hammersmith Medicines Research
Article content BRISBANE, Australia & LONDON — Nucleus Network, a global leader in early phase clinical research, today announced the acquisition of Hammersmith Medicines Research (HMR), one of the United Kingdom's most respected early phase clinical trial organisations. This milestone marks a significant step in Nucleus Network's global growth, establishing the only early phase provider with dedicated facilities in Australia, the United States, and the United Kingdom. Article content The acquisition brings together two organisations with a shared mission: advancing medicine and improving lives. It also honours the legacy of Dr Malcolm Boyce, whose leadership established HMR as a centre of excellence in early phase research across the UK and Europe. With complementary scientific expertise and a strong, mutual commitment to participant safety and ethical conduct, the combined organisation is well positioned to accelerate clinical development and deliver inclusive, high-quality studies across three continents. Article content 'We are deeply honoured by the trust Dr Boyce has placed in us to carry forward HMR's legacy,' said Article content . 'This acquisition is about more than expanding our global footprint. It reflects a genuine alignment of values, culture, and purpose. Together, we are building a platform that will help redefine the way early phase trials are delivered.' Article content A New Standard for Early-Phase Clinical Trials Article content With the acquisition of HMR, Nucleus Network is setting a new global benchmark in the delivery of early-phase clinical trials. Sponsors now benefit from a fully integrated model that combines global reach with deep local expertise. By harnessing the strength of our globally leading and multi-jurisdictional business development team, we will work in close partnership with sponsors to guide trials to the geographic locations that best align with their strategic priorities. Studies can commence in one regulatory environment and seamlessly transition to another, enabled by harmonised processes and consistently high-quality standards, accelerating timelines and reducing operational risk. Article content The expanded geographic footprint expands access to broader and more diverse volunteer and patient populations. This scale supports faster recruitment and more inclusive study designs, both of which are critical for first-in-human and adaptive trial protocols. HMR's decades of scientific and operational excellence complement Nucleus Network's advanced infrastructure and digital capabilities. Together, they bring added precision to study execution and data quality, driving robust outcomes across all sites. Article content Sponsors will experience more streamlined engagement through unified systems, shared best practices, and coordinated project delivery, simplifying the complexities of early-phase trial execution. This integration further strengthens Nucleus Network's position as the most experienced global provider dedicated to early-phase clinical research. Article content At the same time, Nucleus Network will continue to partner with CROs around the world, offering flexible services that complement existing partnerships and extend reach across geographies. Article content ' This acquisition expands what's possible for our sponsors,' Pisarev added. 'It deepens our scientific capabilities, strengthens our operational reach, and reinforces our commitment to delivering life-changing therapies to patients around the world.' Nucleus Network will continue to operate its clinical sites in Brisbane, Melbourne, and Sydney (from ~2026), Australia; Minneapolis, Minnesota; and London, England, ensuring continuity for ongoing studies and trusted relationships. Article content Nucleus Network is the only early-phase clinical research provider with a global footprint, operating dedicated Phase I facilities in Australia, the United States, and the United Kingdom. With over 20 years of experience and more than 1,500 first-in-human studies conducted, Nucleus Network is recognized for its scientific excellence, operational integrity, and commitment to innovation. Article content Article content Article content Article content Contacts Article content Media Contact Article content
CTV News
3 days ago
- CTV News
Bike parade raises funds and awareness for people with Parkinson's disease
A group of cyclists biked around Assiniboine Park to raise money for Parkinson's disease research. A bike parade in Assiniboine Park brought Winnipeggers together to celebrate the Parkinson's community—raising funds and awareness for people with the disease. Cyclists gathered on Friday for the second annual Team 81 Ride for Parkinson's, pedalling approximately 50 kilometres to help Manitobans living with Parkinson's disease. All funds raised will be supporting U-Turn Parkinson's, a Manitoba charity assisting people with Parkinson's through free wellness programs, a range of physical activity programming and community support. 'It's fantastic to see our community get behind us,' said Tim Hague, founder and board chair of U-Turn Parkinson's. 'I'm excited about bringing a disease that's often hidden, often in the shadows, out into the light so that we can make a difference in people's lives.' Hague explained that he was diagnosed with Parkinson's in 2011, a neurodegenerative disease that leads to loss of bodily control. While there is currently no cure, physical activity has been shown to reduce symptoms and slow the disease's progression. Hague said he eventually realized there weren't any exercise or wellness-focused programs available in Winnipeg for people with Parkinson's. 'I was a nurse at the time, so I did what most any nurse would do—take it upon myself to do something about it,' he said. Hague went on to found U-Turn Parkinson's in 2016, which he said now has 20 classes a week with hundreds of participants. 'It's just phenomenal. It shows the need that exists,' said Hague. He said the event's name was chosen after #81 with the Winnipeg Jets, Kyle Connor, who serves as U-Turn Parkinson's ambassador. Connor's father and grandfather both passed away from the neurological disorder. 'No matter what stage you're at in your Parkinson's journey, whether you're newly diagnosed or you've been living with the disease for several years, there's a place for you here,' said Jordana Hague, Tim's daughter and program manager at U-Turn Parkinson's. 'We offer lots of different classes, different modification options—seated, standing, anything—so that everyone who is living with Parkinson's can find something.' -With files from CTV's Glenn Pismenny
